Pfizer has completed its acquisition of the pharmaceutical development company, InnoPharma, following receipt of United States (US) regulatory approval from all government authorities required by the agreement and other closing conditions.
John Young, Group President, Pfizer Global Established Pharma (GEP) said, “We believe this acquisition will help Pfizer build a strong sterile injectables pipeline in areas such as oncology and central nervous disorders. Sterile injectables is one of several areas of potential growth for GEP. This acquisition reflects our continued view that attractive growth opportunities, both external and organic, exist for the business.”
EP News Bureau– Mumbai
- Advertisement -
